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Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown origin. Recent findings suggest that
IPF results from multiple factors that eventually lead to interstitial lung injury. In the pathogenesis it is likely that
complex relationships between genetic predispositions, environmental exposures, and lung infections promote the
fibrotic processes causing IPF; it is this complexity and the multiplicity of causes that make the population and
clinical course of IPF so heterogeneous. Thus, it is clear that one common factor driving IPF pathogenesis in all
patients would be far too simplified of an understanding. In recent years, efforts have been made in finding
therapeutic strategies that target disease progression rather than disease onset. The biochemical composition
and abnormal stiffness of the matrix might be crucial in controlling the cellular phenotype in fibrotic lungs that
promotes disease progression and persistence. Though there has been substantial progress in the IPF field in
recent years, much more work is required in order to improve the prognosis associated with this disease.
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Idiopathic pulmonary fibrosis (IPF) is one of the most
common diseases classified as a rare disease. The progno-
sis of IPF is poor, with most patients succumbing to their
illness at a rate comparable to aggressive cancers [1]. The
causes of IPF remain elusive and are not easy to identify as
patients diagnosed are typically at an advanced stage of
the disease. Several associated risk factors without a clear
causative role have been reported [2], including environ-
mental and occupational exposures, infections, and gen-
etic polymorphisms. To date, there is no ideal therapy for
IPF, but at least two drugs have been approved in recent
years, both demonstrating a significant impact on disease
progression [3, 4]. Understanding the signals involved in
the pathogenesis and progression of IPF remain a critical
component in discovering new therapies, providing early
diagnosis, and preventing disease progression.* Correspondence: kolbm@mcmaster.ca
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Unlike fish or amphibians, evolution has favoured fibro-
genesis over regeneration in complex organisms such as
mammals [5, 6]. Even if the selective advantage provided
by such a “substitution” remains unclear, fibrogenesis
certainly benefits survival by preventing blood loss and
pathogen invasion through mechanisms of wound clos-
ure. The pathological evolution of fibrosis requires the
combination of an initial injury, which starts the healing
process, and impaired wound healing mechanisms. This
view suggests an interaction between environmental and
genetic factors in IPF pathogenesis. Several gene muta-
tions have been identified among IPF patients in recent
years [7], but whether they are direct cause, predispos-
ition factors, or just associations remains unclear. For in-
stance, surfactant protein and mucin gene mutations can
lead to direct epithelial cell injury and death, whereas
telomerase gene mutations predispose the epithelium to
a pathologic response by favouring an abnormal turn-
over and repair. However, these mutations only affect
1 % (surfactant), 35 % (mucins), and 3 % (telomeres) of
IPF patients, leaving more the 60 % of patients without
identified genetic predispositions [8]. Therefore, IPFess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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steps in which genetic mutations could represent just one
of many important components.
Exposure to inhaled environmental agents, most of all
cigarette smoke, represents an important risk factor for
IPF. The increased risk of developing IPF remains even
after smoke cessation, suggesting the establishment of
self-sustained (or autocrine) mechanisms after the initial
injury [9, 10]. Cigarette smoke, in addition to epithelial
injury, also influences epigenetic changes such as DNA
methylation and chromatin modifications that regulate
the expression of genes involved in tissue repair and
which have an impact on IPF pathogenesis [7]. Infec-
tions are common in the IPF population; numerous vi-
ruses and bacteria have the potential to cause epithelial
cell injury and apoptosis [11] and have the capacity to
modulate the host response to injury. In experimental
settings, infections seem only able to worsen fibrosis in
conjugation with other profibrotic stimuli, suggesting
that infections might be co-factors for IPF [12, 13]. In
the past decade, the lack of clinical evidence of an on-
going inflammation, as well as the inefficiency of im-
munosuppressive therapies in IPF, diminished the role of
chronic inflammation in IPF pathogenesis [5]. Neverthe-
less, it cannot be ignored that inflammatory cytokine
and immune cell infiltration are found in IPF [14, 15].
We have shown, in vivo, that interleukin-1β induces an
early inflammation promoting the activation of pro-
fibrotic pathways through transforming growth factor
(TGF)-β1, able to self-sustain up to day 60 independ-
ently of any signs of residual inflammation and trigger
clustering of myofibroblasts and collagen similar to myo-
fibroblastic foci observed in humans [16]. This highlights
complex relations between the initial injury and the im-
paired wound healing that might favour the profibrotic
processes which lead to IPF.
The vicious cycle caused by increased lung stiffness
Myofibroblasts are the major producers of the fibrotic
extracellular matrix (ECM) which results in the charac-
teristic stiffness of a fibrotic lung, decreased lung vol-
umes, and shortness of breath in patients. In vitro, the
differentiation of myofibroblasts is strongly correlated
with substrate stiffness; it is clear that stiff substrates
promote the production of profibrotic mediators and
ECM deposition [17, 18], whereas substrates of physio-
logical stiffness inactivate myofibroblasts and favour
apoptosis [19]. Activation of Rho Kinase and Focal
Adhesion Kinase by increased force tension appears to
have a major role in this process and the inhibition of
these pathways prevents experimental fibrosis [20–22].
The ECM is a storage of growth factors, such as latent
TGF-β1, which are bound to integrins, transmembrane
proteins allowing cell-matrix adhesions. An increase insubstrate stiffness induces mechanical resistance that
favours the release of active TGF-β1 from the integrin pro-
moting myofibroblast activity [23]. These in vitro ap-
proaches strongly suggest that stiffness alone can drive
myofibroblast activation and subsequent ECM deposition.
However, they lack the spatial cues that ECM and growth
factors encounter in the 3D fibrotic lung in vivo. Booth et
al. [24] showed, very elegantly, that decellularised matrix
from IPF but not healthy lungs can drive myofibroblast dif-
ferentiation and accumulation. Even though the difference
in stiffness between non-IPF and IPF lungs was conserved
after decellularisation in these studies, it remains unclear
whether the altered stiffness alone is responsible for the
difference of cell behaviour between the two types of
matrix or whether the abnormal composition of the fi-
brotic ECM also plays a role. Indeed, the “matrisome” of
the IPF lung is completely different from the non-IPF lung
with many more ECM components as well as more latent
TGF-β1 trapped in the matrix [24]. These new techniques
are very useful to mimic the native environment of cells,
but also have limitations including heterogeneous and
non-physiological stiffness of the acellular matrix [25].
Moreover, no study has yet fully described the effect of
decellularisation on ECM component preservation and it is
possible that proteins trapped in the matrix, which may
have a role on cell behaviour, are washed out through the
process. For instance, Parker et al. [26] demonstrated that
the IPF matrix can drive the expression of genes in fibro-
blasts already highly present in the diseased ECM. This
suggests an autocrine feedback loop in which IPF ECM
triggers the upregulation of its own abnormal ECM com-
ponents. This shows that the biochemical composition
could be as important as the stiffness of the matrix in con-
trolling the cellular phenotype in fibrotic lungs [26]. Fur-
ther studies are needed to elucidate the actual contribution
of matrix stiffness and composition on myofibroblast dif-
ferentiation and persistence.Conclusions
IPF is a complex disease involving multiple steps which
eventually overcome physiological repair mechanisms and
lead to fibrosis. Even if the etiologic events causing the on-
set of IPF remain unknown, decades of research have
highlighted the fact that fibrogenesis requires a combin-
ation of several factors which cause both epithelial injury
and impaired wound healing. It is this complexity and the
multiplicity of causes that make the population and clin-
ical course of IPF so heterogeneous. For the time being, it
seems more realistic to continue investigating therapeutic
strategies that limit disease progression rather that prevent
its development. Due to the multiple pathways involved in
abnormal fibrogenesis, multi-target therapies appear
essential.
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